A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic Migraine (NCT07018700)
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter, Clinical Trial With Extension Period to Evaluate the Efficacy and Safety of Xeomin® Injections for the Prevention of Episodic Migraine
🩺 Plain-English Summary (8th-Grade Level)
In this clinical trial, participants with episodic migraine will receive injections with Xeomin or Placebo into muscles of the head and neck. The purpose is to measure the change in monthly migraine days with Xeomin injections compared to Placebo injections. Trial details include: * Trial duration: 52 to 55 weeks; * Screening period: 4 to 5 weeks; * Treatment duration: 4 treatments, each about 12 weeks apart; and * Visit frequency: about every 4 weeks, 14 visits in total. The first and last visit and the 4 treatment visits are on-site, the other 8 visits are remote by phone / video call.
Who can join: Review the eligibility criteria below.
Location: TrialSphere Corp, Merz Investigational Site #0010513 — Chandler, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (109 Sites)
Showing the first 25 of 109 sites.
- TrialSphere Corp, Merz Investigational Site #0010513 — Chandler, Arizona
- Arizona Neuroscience Research, Merz Investigational Site #0010521 — Phoenix, Arizona
- Baptist Health Medical Center, Merz Investigational Site #0010520 — Little Rock, Arkansas
- Chemidox Clinical Trials Inc, Merz Investigational Site #0010488 — Lancaster, California
- Clinical Research Institute, Merz Investigational Site #0010487 — Los Angeles, California
- Clinical Trials Management Services, Merz Investigational Site #0010526 — Thousand Oaks, California
- BNL Health Inc., Merz Investigational Site #0010489 — Torrance, California
- Hasbani Neurology, Merz Investigational Site #0010509 — New Haven, Connecticut
- Yale Center for Clinical Investigations, Merz Investigational Site #0010527 — New Haven, Connecticut
- New England Institute Neurology and Headache, Merz Investigational Site #0010441 — Stamford, Connecticut
- Northwest Florida Clinical Research Group, Merz Investigational Site #0010286 — Gulf Breeze, Florida
- Nexus Clinical Research Center, Merz Investigational Site #0010514 — Homestead, Florida
- Jacksonville Center for Clinical Research, Merz Investigational Site #0010515 — Jacksonville, Florida
- Clinical Research of Central Florida, Merz Investigational Site #0010532 — Lakeland, Florida
- American Research Institute, Merz Investigational Site #0010492 — Miami, Florida
- Premiere Research Institute at Palm Beach Neurology, Merz Investigational Site #0010499 — West Palm Beach, Florida
- Accel Research - NeuroStudies, Merz Investigational Site #0010523 — Decatur, Georgia
- Hawaii Pacific Neuroscience, Merz Investigational Site #0010510 — Honolulu, Hawaii
- Kansas Institute of Research,, Merz Investigational Site #0010495 — Overland Park, Kansas
- Crescent City Headache and Neurology Center, Merz Investigational Site #0010517 — Chalmette, Louisiana
- DelRicht Clinical Research,, Merz Investigational Site #0010518 — New Orleans, Louisiana
- Sinai Hospital of Baltimore, Merz Investigational Site #0010505 — Baltimore, Maryland
- MedVadis Research, Merz Investigational Site #0010524 — Waltham, Massachusetts
- Mass Institute of Clinical Research, Merz Investigational Site #0010506 — Westborough, Massachusetts
- Vida Clinical Studies, Merz Investigational Site #0010498 — Dearborn Heights, Michigan
📞 Contact the Study Coordinator
Phone: +49691503
Email: clinicaltrials@merz.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Episodic Migraine
- A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine — Huntsville, Alabama
- A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Episodic Migraine in Adults — Birmingham, Alabama
- Efficacy of Nerve Blocks for Episodic Migraine — Rochester, Minnesota
- Chiropractic Care for Episodic Migraine — Boston, Massachusetts
- A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine — Huntsville, Alabama
Explore by condition: All Episodic Migraine clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.